Necim Yalçın, I. Ureyen, Aysun Alcı, Mustafa Gokkaya, A. Kahraman, G. Sel, Gülsüm Ekin Sarı, T. Toptaş
Objectives: The present study aimed to evaluate the operation results of patients who were followed up due to breast cancer and were operated on due to gynecological pathologies or for prophylactic purposes, and determine the distribution of gynecological pathologies in breast cancer patients Study design: Patients with breast cancer who had gynecological surgery in our institution between December 2015 and January 2023 were retrospectively analyzed in this cross-sectional study. The pathological reports and medical records of the included patients were obtained from the gynecologic oncology electronic database system and the patient files. The study is approved by the institution’s local ethics committee. Results: Totally 57 patients with a history of breast cancer had gynecological operations between December 2015 and January 2023. The median age of the patients was 49. Benign pathologies were detected in the majority of patients with a history of breast cancer, this rate was found to be 87.7%. The pathology revealed malignant/premalignant disease in seven (12.2%) patients. Among these seven patients, four patients had malignant disease one patient had microinvasive cervical cancer, one patient had ovarian serous cancer, one patient had cervical and ovarian metastasis of breast cancer, and one patient had ovarian metastasis of breast cancer. Conclusions: Patients with a history of breast cancer have increased rates of gynecological pathology development compared to the normal population.
{"title":"Evaluation of Pathology Results of Patients with a History of Breast Cancer who were Operated on for Gynecological Pathologies or Prophylaxis","authors":"Necim Yalçın, I. Ureyen, Aysun Alcı, Mustafa Gokkaya, A. Kahraman, G. Sel, Gülsüm Ekin Sarı, T. Toptaş","doi":"10.21613/gorm.2023.1451","DOIUrl":"https://doi.org/10.21613/gorm.2023.1451","url":null,"abstract":"Objectives: The present study aimed to evaluate the operation results of patients who were followed up due to breast cancer and were operated on due to gynecological pathologies or for prophylactic purposes, and determine the distribution of gynecological pathologies in breast cancer patients\u0000Study design: Patients with breast cancer who had gynecological surgery in our institution between December 2015 and January 2023 were retrospectively analyzed in this cross-sectional study. The pathological reports and medical records of the included patients were obtained from the gynecologic oncology electronic database system and the patient files. The study is approved by the institution’s local ethics committee. \u0000Results: Totally 57 patients with a history of breast cancer had gynecological operations between December 2015 and January 2023. The median age of the patients was 49. Benign pathologies were detected in the majority of patients with a history of breast cancer, this rate was found to be 87.7%. The pathology revealed malignant/premalignant disease in seven (12.2%) patients. Among these seven patients, four patients had malignant disease one patient had microinvasive cervical cancer, one patient had ovarian serous cancer, one patient had cervical and ovarian metastasis of breast cancer, and one patient had ovarian metastasis of breast cancer.\u0000Conclusions: Patients with a history of breast cancer have increased rates of gynecological pathology development compared to the normal population.","PeriodicalId":507263,"journal":{"name":"Gynecology Obstetrics & Reproductive Medicine","volume":" 38","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140213104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OBJECTIVE: We aim to compare the effectiveness of oral contraceptives and dienogest, primarily by considering the quality of life scale. We also aim to compare the Cancer Antigen-125 and Anti-mullerian Hormone values. STUDY DESIGN: Gynecological examination findings evaluated based on ESHRE and ASRM Guideline criteria are compatible with endometriosis, or a previous surgery pathology result is consistent with endometriosis, and patients whose imaging report was compatible with endometriosis were selected. Among the patients who were recommended medical treatment, patients selected as Dionegest 2mg+Ethinylestradiol 0.03 mg (Dienelle) treatment were considered Group 1, and patients deemed suitable for treatment with treatment 2mg Dionegest (Visanne) were considered Group 2. Pre-treatment Cancer Antigen-125/Anti-mullerian Hormone values and SF-36 were recorded. RESULTS: There was no significant difference between drug groups in terms of education status, body mass index, family history, smoking, alcohol consumption, age, age at menarche, menstruation pattern, duration of menstruation, infertility, gestational status, job loss due to pain complaints, operation, and MRI findings (p>0.05). There was no significant difference between the drug groups regarding the quality of life before and after treatment (p>0.05). There was no significant difference between drug groups regarding endometrioma size, Cancer Antigen-125, and anti-mullerian hormone findings (p>0.05). CONCLUSION: Evaluating our data, the efficacy and success of the two treatment protocols were the same. It seems more logical to prefer cost-effective oral contraceptive treatments with a low side-effect profile than high-cost Dionegest. Following the guidelines accepted step therapy in treating mild or moderate endometriosis, cyclic oral contraceptives may be recommended as first-line therapy.
{"title":"Impact of Dienogest Alone or in Combination with Ethinylestradiol on the Quality of Life of Women with Endometriosis: A Prospective Cohort Study","authors":"Mujde Canbay, Suleyman Salman","doi":"10.21613/gorm.2023.1453","DOIUrl":"https://doi.org/10.21613/gorm.2023.1453","url":null,"abstract":"OBJECTIVE: We aim to compare the effectiveness of oral contraceptives and dienogest, primarily by considering the quality of life scale. We also aim to compare the Cancer Antigen-125 and Anti-mullerian Hormone values. STUDY DESIGN: Gynecological examination findings evaluated based on ESHRE and ASRM Guideline criteria are compatible with endometriosis, or a previous surgery pathology result is consistent with endometriosis, and patients whose imaging report was compatible with endometriosis were selected. Among the patients who were recommended medical treatment, patients selected as Dionegest 2mg+Ethinylestradiol 0.03 mg (Dienelle) treatment were considered Group 1, and patients deemed suitable for treatment with treatment 2mg Dionegest (Visanne) were considered Group 2. Pre-treatment Cancer Antigen-125/Anti-mullerian Hormone values and SF-36 were recorded. RESULTS: There was no significant difference between drug groups in terms of education status, body mass index, family history, smoking, alcohol consumption, age, age at menarche, menstruation pattern, duration of menstruation, infertility, gestational status, job loss due to pain complaints, operation, and MRI findings (p>0.05). There was no significant difference between the drug groups regarding the quality of life before and after treatment (p>0.05). There was no significant difference between drug groups regarding endometrioma size, Cancer Antigen-125, and anti-mullerian hormone findings (p>0.05). CONCLUSION: Evaluating our data, the efficacy and success of the two treatment protocols were the same. It seems more logical to prefer cost-effective oral contraceptive treatments with a low side-effect profile than high-cost Dionegest. Following the guidelines accepted step therapy in treating mild or moderate endometriosis, cyclic oral contraceptives may be recommended as first-line therapy.","PeriodicalId":507263,"journal":{"name":"Gynecology Obstetrics & Reproductive Medicine","volume":"70 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139172007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gonca Ozten Dere, Cagman Tan, S. Mumusoglu, Pınar Zarakolu, G. Bozdag
OBJECTIVE: The primary objective of our study was to compare the endometrial microbiota profiles of women with unexplained infertility and fertile women. STUDY DESIGN: A total of 15 patients with unexplained infertility and 15 patients who had a live birth in the last two years with proven fertility were recruited. Endometrial samples were collected and analyzed through next-generation sequencing of the bacteria-specific 16S ribosome gene. RESULTS: Lactobacillus species represented the majority of the microbiome profile in both groups. The median percentage of the endometrial Lactobacillus between infertile patients and fertile patients was not statistically significant (p=0.9). Groups were divided into two categories: Lactobasillus dominant (Lactobacillus spp.> 90%, LD) and Non-Lactobasillus dominant (NLD). Lactobacillus dominance was detected in six of nine patients (66.7%) in the study group and four of nine patients (44.5%) in the control group, and no significant difference was observed between them (p=0.64). CONCLUSION: According to our study results, no significant difference was observed between the endometrial microbiota profile of infertile and fertile patients. Further studies with larger sample sizes are needed to characterize the endometrial microbiota and its impact on reproduction.Keywords: Microbiota, unexplained infertility, endometrial microbiota
{"title":"Comparison of Endometrial Microbiota Results Between Patients with Unexplained Infertility and Fertile Patients through 16s rRNA Sequencing","authors":"Gonca Ozten Dere, Cagman Tan, S. Mumusoglu, Pınar Zarakolu, G. Bozdag","doi":"10.21613/gorm.2023.1452","DOIUrl":"https://doi.org/10.21613/gorm.2023.1452","url":null,"abstract":"OBJECTIVE: The primary objective of our study was to compare the endometrial microbiota profiles of women with unexplained infertility and fertile women. STUDY DESIGN: A total of 15 patients with unexplained infertility and 15 patients who had a live birth in the last two years with proven fertility were recruited. Endometrial samples were collected and analyzed through next-generation sequencing of the bacteria-specific 16S ribosome gene. RESULTS: Lactobacillus species represented the majority of the microbiome profile in both groups. The median percentage of the endometrial Lactobacillus between infertile patients and fertile patients was not statistically significant (p=0.9). Groups were divided into two categories: Lactobasillus dominant (Lactobacillus spp.> 90%, LD) and Non-Lactobasillus dominant (NLD). Lactobacillus dominance was detected in six of nine patients (66.7%) in the study group and four of nine patients (44.5%) in the control group, and no significant difference was observed between them (p=0.64). CONCLUSION: According to our study results, no significant difference was observed between the endometrial microbiota profile of infertile and fertile patients. Further studies with larger sample sizes are needed to characterize the endometrial microbiota and its impact on reproduction.Keywords: Microbiota, unexplained infertility, endometrial microbiota","PeriodicalId":507263,"journal":{"name":"Gynecology Obstetrics & Reproductive Medicine","volume":"13 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139173450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：